Osimertinib in first-line treatment-is a comparison not proof?

被引：2
|
作者：
Cadranel, Jacques [1 ,2 ,3 ]
机构：
[1] Hop Tenon, AP HP, Chest Dept, Paris, France
[2] Hop Tenon, AP HP, Expert Ctr Thorac Oncol, Paris, France
[3] Pierre & Marie Curie Univ Paris 6, Paris, France
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷 / 03期
关键词：
CELL LUNG-CANCER; OPEN-LABEL; EGFR MUTATIONS; ASIAN PATIENTS; SURVIVAL-DATA; PHASE-III; AFATINIB; GEFITINIB; ERLOTINIB; CHEMOTHERAPY;
D O I：
10.21037/atm.2017.12.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [22] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [23] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
    Lotte Westerink
    Jelmer L. J. Nicolai
    Carl Samuelsen
    Hans J. M. Smit
    Pieter E. Postmus
    Ingolf Griebsch
    Maarten J. Postma
    The European Journal of Health Economics, 2020, 21 : 931 - 943
  • [24] Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
    McCully, Belinda H.
    Kozuma, Kaiya
    Pommier, SuEllen
    Pommier, Rodney F.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (05) : 2996 - 3002
  • [25] Patients with uncommon EGFR mutations also benefit from first-line osimertinib
    Diana Romero
    Nature Reviews Clinical Oncology, 2024, 21 : 84 - 84
  • [26] Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
    Ammann, Markus
    Kinney, Michelle A. O.
    Gudmundsdottir, Hallbera
    Santol, Jonas
    Thiels, Cornelius A.
    Warner, Susanne G.
    Truty, Mark J.
    Kendrick, Michael L.
    Smoot, Rory L.
    Anderson, Alexandra L.
    Halfdanarson, Thorvardur R.
    Nagorney, David M.
    Starlinger, Patrick P.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (06) : 3976 - 3977
  • [27] Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
    Belinda H. McCully
    Kaiya Kozuma
    SuEllen Pommier
    Rodney F. Pommier
    Annals of Surgical Oncology, 2024, 31 : 2996 - 3002
  • [28] Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
    Lesley J. Scott
    Drugs & Therapy Perspectives, 2019, 35 : 50 - 50
  • [29] First-line Therapy for NSCLC: Is Amivantamab-Lazertinib better than Osimertinib?
    Simon, Annika
    PNEUMOLOGIE, 2024, 78 (12):
  • [30] Patients with uncommon EGFR mutations also benefit from first-line osimertinib
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (02) : 84 - 84
12345